Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.17), $0.05 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $24.19 million versus the consensus estimate of $23.63 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.